Who to call at Arecor Therapeutics PLC, and when

Fundz watches for the moments Arecor Therapeutics PLC starts buying, and tells you who to reach.

An alert the day Arecor Therapeutics PLC raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Arecor Therapeutics PLC, from your own LinkedIn network

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Arecor Therapeutics Signs Co-development Agreement with Sequel Med Tech for AT278 and Secures Up to $11 Million in Funding.

Sep 25, 2025

Contract Type

agreement

CambridgeBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Arecor Therapeutics has announced a significant co-development agreement with Sequel Med Tech for the AT278 insulin product. The agreement includes a royalty financing arrangement to raise up to $11 million, which will accelerate the development of AT278 and support Arecor’s growth strategy.

Company Information

Company

Arecor Therapeutics PLC

Location

Cambridge, England, United Kingdom

About

Arecor Therapeutics PLC is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.